Show simple item record

dc.contributor.authorGalanina, N.
dc.contributor.authorSmith, S.M.
dc.contributor.authorLiao, C.
dc.date.accessioned2019-06-21T18:46:23Z
dc.date.available2019-06-21T18:46:23Z
dc.date.issued2018
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85017531430&doi=10.1111%2fbjh.14544&partnerID=40&md5=ad27526ec053ee8d3efd37b0551bbb9e
dc.identifier.urihttp://hdl.handle.net/10713/9653
dc.description.sponsorshipSupported by NCI contract N01-CM-2011-00071C.en_US
dc.description.urihttps://dx.doi.org/10.1111/bjh.14544en_US
dc.language.isoen-USen_US
dc.publisherBlackwell Publishing Ltden_US
dc.relation.ispartofBritish Journal of Haematology
dc.subjectMEK inhibitionen_US
dc.subjectnovel therapiesen_US
dc.subjectrelapsed/refractory DLBCLen_US
dc.subjectselumetiniben_US
dc.titleUniversity of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCLen_US
dc.typeArticleen_US
dc.identifier.doi10.1111/bjh.14544
dc.identifier.pmid28419407


This item appears in the following Collection(s)

Show simple item record